The round was led by MagnaSci Ventures, with participation from Evotec, Alexandria Venture Investments, MP Healthcare Venture Management, Red Apple Group, and WS Investments. In connection with the Series A financing, Brian T. Dorsey, Founding Partner at MagnaSci Ventures, will be joining Forge’s Board of Directors.
The company intends to use the funds to advance its LpxC inhibitor into clinical studies.
Led by Zachary A. Zimmerman, Ph.D., CEO, Forge Therapeutics is a biopharmaceutical company developing novel antibiotics to treat multi-drug resistant bacteria, or ‘superbugs,’ that have ignited a global health epidemic. With its proprietary chemistry approach, the company develops small molecule inhibitors targeting metalloenzymes. Its lead effort is focused on LpxC, a zinc metalloenzyme found only in Gram-negative bacteria essential for bacteria to grow.
FinSMEs
25/04/2017